Exelixis, Inc. (EXEL)
44.81
+1.03
(+2.35%)
USD |
NASDAQ |
Jan 21, 16:00
44.73
-0.08
(-0.18%)
Pre-Market: 09:15
Exelixis Free Cash Flow: 779.77M for Sept. 30, 2025
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Vanda Pharmaceuticals, Inc. | -82.95M |
| ADMA Biologics, Inc. | 40.61M |
| Aldeyra Therapeutics, Inc. | -40.08M |
| Natera, Inc. | 93.56M |
| Merck & Co., Inc. | 13.05B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 290.32M |
| Cash from Investing (Quarterly) | 25.40M |
| Cash from Financing (Quarterly) | -103.86M |
| Free Cash Flow Per Share (Quarterly) | 1.037 |
| Free Cash Flow to Equity (Quarterly) | 292.22M |
| Free Cash Flow to Firm (Quarterly) | 288.84M |
| Free Cash Flow Yield | 6.08% |